4.8 Article

Bayesian Inference Elucidates the Catalytic Competency of the SARS-CoV-2 Main Protease 3CLpro

Journal

ANALYTICAL CHEMISTRY
Volume 95, Issue 40, Pages 14981-14989

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.analchem.3c02459

Keywords

-

Ask authors/readers for more resources

The main protease 3CL(pro) of SARS-CoV-2 is a dimeric enzyme that plays a crucial role in viral replication. This study used enzymatic methods to characterize the dimerization and catalytic efficiency of SARS-CoV-2 3CL(pro) and found that the enzyme forms a dimer at pH 7.5 with high catalytic activity. The enzymatic activity decreases in solutions of high ionic strength.
The main protease of SARS-CoV-2, 3CL(pro), is a dimeric enzyme that is indispensable to viral replication and presents an attractive opportunity for therapeutic intervention. Previous reports regarding the key properties of 3CL(pro) and its highly similar SARS-CoV homologue conflict dramatically. Values of the dimeric K-d and enzymic k(cat)/K-M differ by 10(6)- and 10(3)-fold, respectively. Establishing a confident benchmark of the intrinsic capabilities of this enzyme is essential for combating the current pandemic as well as potential future outbreaks. Here, we use enzymatic methods to characterize the dimerization and catalytic efficiency of the authentic protease from SARS-CoV-2. Specifically, we use the rigor of Bayesian inference in a Markov Chain Monte Carlo analysis of progress curves to circumvent the limitations of traditional Michaelis-Menten initial rate analysis. We report that SARS-CoV-2 3CL(pro) forms a dimer at pH 7.5 that has K-d = 16 +/- 4 nM and is capable of catalysis with k(cat) = 9.9 +/- 1.5 s(-1), KM = 0.23 +/- 0.01 mM, and k(cat)/K-M = (4.3 +/- 0.7) x 10(4) M-1 s(-1). We also find that enzymatic activity decreases substantially in solutions of high ionic strength, largely as a consequence of impaired dimerization. We conclude that 3CL(pro) is a more capable catalyst than appreciated previously, which has important implications for the design of antiviral therapeutic agents that target 3CL(pro).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available